{"id":902568,"date":"2025-10-29T20:03:48","date_gmt":"2025-10-30T00:03:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/"},"modified":"2025-10-29T20:03:48","modified_gmt":"2025-10-30T00:03:48","slug":"ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/","title":{"rendered":"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ROCKVILLE, Md. and SUZHOU, China, Oct.  29, 2025  (GLOBE NEWSWIRE) &#8212; Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201c<strong>Ascentage Pharma<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company&#8217;s management is scheduled to participate in the following investor conferences in November 2025.<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Goldman Sachs APAC Healthcare Corporate Day 2025: <\/strong>One-on-one and group investor meetings on November 5<\/li>\n<li style=\"text-align:justify\">\n          <strong>Stifel 2025 Healthcare Conference:<\/strong> Presentation on\u00a0November 13 at\u00a02:40 pm EST<\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About Ascentage Pharma Group International<\/strong>\n      <\/p>\n<p align=\"justify\">Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201c<strong>Ascentage Pharma<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key apoptotic pathway proteins, such as Bcl-2, MDM2, p53 as well as next-generation kinase inhibitors.<\/p>\n<p align=\"justify\">The Company\u2019s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with chronic myelogenous leukemia (CML) in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), called POLARIS-1, and succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) patients, called POLARIS-3.<\/p>\n<p align=\"justify\">The Company\u2019s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China\u2019s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who have previously received at least one systemic therapy including Bruton\u2019s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL\/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL\/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia ( AML); and the FDA-cleared GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS).<\/p>\n<p align=\"justify\">Leveraging its robust R&amp;D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https:\/\/ascentage.com\/<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma\u2019s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma\u2019s filings with the\u00a0SEC, including those set forth in the sections titled \u201cRisk factors\u201d and \u201cCautionary note regarding forward-looking statements\u201d in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections headed \u201cForward-looking Statements\u201d and \u201cRisk Factors\u201d in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and\/or The Stock Exchange of Hong Kong Limited it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute profit forecast by the Company\u2019s management.<\/p>\n<p align=\"justify\">As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma\u2019s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Investor Relations:<\/strong><br \/>\n        <br \/>Hogan Wan, Head of IR and Strategy<br \/>Ascentage Pharma<br \/>Hogan.Wan@ascentage.com<br \/>+86 512 85557777<\/p>\n<p>Stephanie Carrington<br \/>ICR Healthcare<br \/>AscentageIR@icrhealthcare.com<br \/>+1 (646) 277-1282<\/p>\n<p>\n        <strong>Media Relations:<\/strong><br \/>\n        <br \/>Jon Yu<br \/>ICR Healthcare<br \/>AscentagePR@icrhealthcare.com<br \/>+1 (646) 677-1855<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDc2NiM3MjMxNzg1IzIyOTU2ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDM3MzJiZDgtZGFjNy00ZjJkLWEyNjYtNjg5ODlhMDI3ZDlkLTEzMDcyMzEtMjAyNS0xMC0zMC1lbg==\/tiny\/ASCENTAGE-PHARMA-GROUP-INTERNA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) &#8212; Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201cAscentage Pharma\u201d or the \u201cCompany\u201d), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company&#8217;s management is scheduled to participate in the following investor conferences in November 2025. Goldman Sachs APAC Healthcare Corporate Day 2025: One-on-one and group investor meetings on November 5 Stifel 2025 Healthcare Conference: Presentation on\u00a0November 13 at\u00a02:40 pm EST About Ascentage Pharma Group International Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201cAscentage Pharma\u201d or the \u201cCompany\u201d) is a global, commercial stage, integrated biopharmaceutical company engaged in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-902568","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) &#8212; Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201cAscentage Pharma\u201d or the \u201cCompany\u201d), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company&#8217;s management is scheduled to participate in the following investor conferences in November 2025. Goldman Sachs APAC Healthcare Corporate Day 2025: One-on-one and group investor meetings on November 5 Stifel 2025 Healthcare Conference: Presentation on\u00a0November 13 at\u00a02:40 pm EST About Ascentage Pharma Group International Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201cAscentage Pharma\u201d or the \u201cCompany\u201d) is a global, commercial stage, integrated biopharmaceutical company engaged in &hellip; Continue reading &quot;Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T00:03:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDc2NiM3MjMxNzg1IzIyOTU2ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025\",\"datePublished\":\"2025-10-30T00:03:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/\"},\"wordCount\":841,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDc2NiM3MjMxNzg1IzIyOTU2ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/\",\"name\":\"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDc2NiM3MjMxNzg1IzIyOTU2ODE=\",\"datePublished\":\"2025-10-30T00:03:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDc2NiM3MjMxNzg1IzIyOTU2ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDc2NiM3MjMxNzg1IzIyOTU2ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025 - Market Newsdesk","og_description":"ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) &#8212; Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201cAscentage Pharma\u201d or the \u201cCompany\u201d), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company&#8217;s management is scheduled to participate in the following investor conferences in November 2025. Goldman Sachs APAC Healthcare Corporate Day 2025: One-on-one and group investor meetings on November 5 Stifel 2025 Healthcare Conference: Presentation on\u00a0November 13 at\u00a02:40 pm EST About Ascentage Pharma Group International Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (\u201cAscentage Pharma\u201d or the \u201cCompany\u201d) is a global, commercial stage, integrated biopharmaceutical company engaged in &hellip; Continue reading \"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-30T00:03:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDc2NiM3MjMxNzg1IzIyOTU2ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025","datePublished":"2025-10-30T00:03:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/"},"wordCount":841,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDc2NiM3MjMxNzg1IzIyOTU2ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/","name":"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDc2NiM3MjMxNzg1IzIyOTU2ODE=","datePublished":"2025-10-30T00:03:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDc2NiM3MjMxNzg1IzIyOTU2ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDc2NiM3MjMxNzg1IzIyOTU2ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-november-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/902568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=902568"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/902568\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=902568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=902568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=902568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}